Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Arvia E. Morris"'
Autor:
Brittney Livingston, Arvia E. Morris, Peter G. Slade, Lowell J. Brady, Robert Bailey, Craig Zupke, Lisa Taylor, Kyle Bigham, Philip Clark, R. Guy Caspary
Publikováno v:
Biotechnology Progress. 31:1433-1441
Pressures for cost-effective new therapies and an increased emphasis on emerging markets require technological advancements and a flexible future manufacturing network for the production of biologic medicines. The safety and efficacy of a product is
Autor:
Chris B. Russell, Rebecca E. Mccoy, Arvia E. Morris, Dina Fomina-Yadlin, John J. Gosink, Brian D. Follstad, Jeffrey T. McGrew
Publikováno v:
Biotechnology and Bioengineering. 111:965-979
Depletion of two nonessential amino acids, asparagine (Asn) and glutamine (Gln), occurred during a fed-batch production process with a CHO cell line expressing a recombinant antibody. This depletion coincided with growth suppression and the onset of
Autor:
Teri L. Aldrich, Frederick W. Jacobsen, Rupa Padaki, Taruna Arora, Martin J. Allen, Jennifer C. Lavallee, Richard J. Armitage, Arvia E. Morris
Publikováno v:
The Journal of Immunology. 186:341-349
Studies for vaccine and human therapeutic Ab development in cynomolgus monkeys (cynos) are influenced by immune responses, with Ab responses playing a significant role in efficacy and immunogenicity. Understanding the nature of cyno humoral immune re
Publikováno v:
Biotechnology Progress. 19:1433-1438
Over the past 10 years, monoclonal antibodies and antibody fragments have become an increasingly important source of therapeutic molecules in the biotechnology industry. Drug development strategies rely on screening large numbers of candidate molecul
Autor:
David Treiber, Brian D. Follstad, Zhimei Du, Yuling Zhang, Pranhitha Reddy, Brad Dell, Carole Heath, Dina Fomina-Yadlin, Ramsey A. Saleem, Arvia E. Morris, Craig Zupke, Matthew Leith, Brent Grisim, John D. McCarter, Rebecca E. Mccoy, Tharmala Tharmalingam
Publikováno v:
Biotechnology and Bioengineering
The continued need to improve therapeutic recombinant protein productivity has led to ongoing assessment of appropriate strategies in the biopharmaceutical industry to establish robust processes with optimized critical variables, that is, viable cell
Autor:
Ralph Klinke, Richard L. Remmele, William C. Fanslow, Richard J. Armitage, Arvia E. Morris, Brian M. Macduff
Publikováno v:
Journal of Biological Chemistry. 274:418-423
Recent progress in the understanding of immune function indicates that the interaction of CD40L with its receptor, CD40, plays a pivotal role in both humoral immunity and cell-mediated defense against pathogens. Functional studies of this interaction
Publikováno v:
Cytotechnology. 28:9-17
We have recently reported on the isolation of a 5.7 kb segment of Chinese hamster ovary cell genomic DNA, Expression Augmenting Sequence Element (EASE), which when used in bicistronic expression vectors allows the development of stable Chinese hamste
Autor:
Douglas E. Williams, Hilary J. McKenna, Chi Chang Lee, Kenneth Brasel, Stewart D. Lyman, Philip J. Morrissey, Arvia E. Morris, Keith Charrier
Publikováno v:
Blood. 88:2004-2012
We have investigated the effects of in vivo treatment with flt3 ligand (FL) on murine hematopoiesis, including mobilization of progenitors into the peripheral blood (PB). Mice were injected once daily with 10 micrograms recombinant human FL for 15 da
Autor:
Ralph Klinke, Arvia E. Morris, James E. Matsuura, Emory H. Braswell, Richard L. Remmele, Wayne R. Gombotz, Randal R. Ketchem
Publikováno v:
Archives of biochemistry and biophysics. 392(2)
The CD40 ligand molecule is unique, consisting of a receptor-binding domain anchored by an isoleucine zipper moiety. Exact determination of the multimeric state and its tendency to form molten globules has not been elucidated. Corroborating evidence
Publikováno v:
Animal Cell Technology: From Target to Market ISBN: 9789401038973
As more genes are being identified through genomic techniques,the need to rapidly express recombinant proteins for functionalstudies has become increasingly acute. Transient expression ofrecombinant protein using COS-1, CV-1 and 293 cells is widelyus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c813144094e51a14a6e1a80b38d1a1f7
https://doi.org/10.1007/978-94-010-0369-8_9
https://doi.org/10.1007/978-94-010-0369-8_9